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INTRODUCTION
Pulmonary hypertension (PH) described in valvular
heart disease (VHD) is frequent and belongs to the
group 2 corresponding to PH related to left heart
disease according to the new classification of
PH. 1 Diagnosis of PH related to VHD is based on
the following criteria: mean pulmonary arterial
pressure (PAP) greater than 25 mm Hg associated
with pulmonary capillary wedge pressure (PCWP)
or left ventricular (LV) end-diastolic pressure
greater than 15 mm Hg. The increase of LV volume
or pressure in VHD induces a rise of left atrial (LA)
pressure, which causes a passive backward trans-
mission to the pulmonary venous system with
subsequent increase of PH. 2 Persistent high pul-
monary venous pressure can induce irreversible
vasculature vasoconstriction and hyperplasia
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KEY POINTS
 Pulmonary hypertension (PH) is a classical pathophysiologic consequence of left-sided valvular
heart disease (VHD). Aortic and mitral valve (stenosis and regurgitation) diseases are frequently
accompanied by PH, especially when they are severe and symptomatic.
 In asymptomatic patients, PH is rare, although the exact prevalence is unknown and mainly stems
from the severity of the VHD and the presence of diastolic dysfunction. Recently, exercise echocar-
diography has gained interest in depicting PH.
 In these asymptomatic patients, exercise PH is observed in about greater than 40%. Either PH at
rest or during exercise is also a powerful determinant of outcome and is independently associated
with reduced survival, regardless of the severity of the underlying valvular pathology.
 PH is a marker of poor prognosis; assessment of PH in VHD is crucial for risk stratification and man-
agement of patients with VHD.
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contributing to further increase in PH, excessive
regarding PCWP.3 At advanced stage of VHD,
chronic PH contributes to increased right ventricu-
lar (RV) afterload and leads to progressive RV
remodeling, including RV hypertrophy followed
by RV dilatation. It leads to increased tricuspid
regurgitation (TR) severity and RV dysfunction.
When PH occurs in VHD, it is frequently associated
with clinical symptoms ( ).Fig. 1
Echoca rdiogr aphy gives an estimation of sys-
tolic PAP (s PAP) and play s a ke y role in assess -
ment of VHD and conseq uences of PH, in
partic ular on RV functio n ( ). In someTable 1
cases, rig ht hear t catheter izatio n is manda tory
to determ ine accur ate value of PC WP and
confirm d iagnos is. Many i ndices ha ve been
devel ope d for quantif ying RV function , but
refer en ce standards for RV func tional assess -
ment are lacking.4 , 5 The developm ent of three-
dimensi onal echoca rdiogr aphy and cardiac
magnetic resonanc e provid es a bet ter evalu ation
of RV volume an d g eometry th an conven tional
two-dim ension al e chocar diogr aphy. 2 , 6
Because PH is a marker of poor prognosis,
assessment of PH in VHD is crucial for risk stratifi-
cation and management of patients ( ). TheTable 2
impact of RV function on outcomes of VHD has
been underestimated for a long time,7 whereas it
is now clearly established that RV failure compro-
mises patient outcomes in VHD. 2,8
RESTING PULMONARY HYPERTENSION
AND AORTIC STENOSIS
Prevalence of resting PH in aortic stenosis (AS) is
difficult to establish because it depends on clinical
profile and definition of PH. Lancellotti and col-
leagues 9 reported only 6% of resting PH in a series
of 105 patients presenting with asymptomatic AS,
whereas the prevalence of PH could range from
Fig. 1. Hemodynamic, structural, and functional changes induced by left-sided valvular.
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47% to 65% in patients with symptomatic aortic
disease. 10,11 Roselli and colleagues 12 found that
74% of patients with severe AS presented with
moderate (sPAP from 35 to 50 mm Hg) to severe
(sPAP >50 mm Hg) PH, as assessed by echocardi-
ography. However, the level and the severity of PH
depends more on diastolic burden that the severity
of AS. 10,13
The presence of PH is a sign of advanced dis-
ease stage. It has been found that moderate to
severe PH was associated with poor prognosis
in cases of conservative therapy. 14 Indeed,
several studies identified elevated PH at baseline
as an independent predictive factor for early and
late mortality after aortic valve replacement
(AVR), whereas patients with normal PH at base-
line presented a good prognosis. 15 Melby and
colleagues 11 showed that patients with PH had
a higher risk of operative mortality than without
PH (5.4% vs 9.3%; .02). Interestingly, the de-P 5
gree/level of preoperative PH seemed to be asso-
ciated with the postoperative survival rates.
Roselli and colleagues 12 demonstrated that pa-
tients with severe PH (sPAP >50 mm Hg) had
the worst prognosis (31% 10-year survival). Bar-
barsh and colleagues 16 found similar results in
case of transcatheter aortic valve implantation
(TAVR): severe PH at baseline is a predictive fac-
tor of mortality at 1 year after performing TAVR in
a group of 415 patients with symptomatic AS. It
has been demonstrated that PH may be
reversible, at least partially, because remodeling
of pulmonary vasculature and may decrease after
AVR or TAVR, 12 in particular in patients with
higher preoperative PCWP.14 Nevertheless,
persistent PH after procedure is associated with
adverse outcomes. 11
Although preoperative PH was clearly associ-
ated with early and late postoperative morbidity
and mortality, actual recommendations consider
resting PH as a trigger for AVR or TAVR.17,18
Optimal timing of AVR or TAVR in asymptomatic
severe AS remains challenging.2 Therefore, PH is
often associated with symptoms and its presence
might suggest hidden symptoms in apparently
asymptomatic patents, classically in elderly pa-
tients with limited activities.19 In practice, AVR
should be considered in patients with PH at rest
if confirmed by a right heart catheterization and if
the risk of intervention is perfectly weighted.17
RESTING PULMONARY HYPERTENSION AND
PRIMARY/SECONDARY MITRAL
REGURGITATION
Primary and secondary mitral regurgitation (MR)
are common causes of resting PH and its preva-
lence depends on MR severity, clinical status,
and LV systolic function.19 Ghoreishi and col-
leagues20 reported significant PH (sPAP >50 mm
Hg) in 20% to 30% of patients with severe primary
MR and up to 64% in symptomatic patients
Table 1















RA area <18 cm2
Normal >105 ms Unlikely/low
2.8 m/s
















RV < LV size
















Presence or not of supportive signs
Other supportive signs are: pulmonary artery diameter greater than 25 mm, early diastolic pulmonary regurgitation ve-
locity greater than 2.2 m/s.
Abbreviations: AT, acceleration time; RA, right atrial; sPAP, systolic pulmonary arterial pressure; VC, vena cava.







































































































































































































































































































































































































































































































































































































































































with New York Heart Association functional class
III-IV. Greater than 40% of patients presenting
with secondary MR and LV dysfunction experi-
enced moderate-severe PH. 21,22 Resting PH may
be also found in MR and preserved LV function. 23
In cases of primary MR, it has been previously
demonstrated that PH at baseline was a powerful
predictor of poor outcomes in terms of survival,
heart failure symptoms, LV function, and LV
remodeling whatever initial LV function or clinical
status. 20,22,24,25 In patients with severe primary
MR and preserved LV function, initial PH was
associated with postoperative LV dysfunction (LV
ejection fraction [LVEF] <50%). Barbieri and col-
leagues 24 reported in a large study that PH was
a strong independent predictive factor of all-
cause mortality, cardiovascular mortality, and
heart failure in degenerative MR. Le Tourneau
and colleagues 26 found similar results and sug-
gested that pre-existing PH doubled the risk of
postoperative mortality or heart failure after adjust-
ment for cofactors at 8 years of follow-up. Mentias
and colleagues27 showed a greater relationship
between the level of pre-existing PH and reduced
postoperative survival. Previous data supported
that early surgery might be beneficial in patients
with PH whatever LV function or clinical status.
Resting PH (sPAP >50 mm Hg) has been consid-
ered as a determinant criterion to trigger mitral
valve repair in patients presenting with primary se-
vere MR and no LV dysfunction or dilatation ac-
cording to international recommendations (class
IIa indication). 17
In cases of secondary MR, similar results have
been found. Resting PH was an independent pre-
dictive factor of death and congestive heart fail-
ure.22,28 Miller and colleagues 22 reported a 30%
increase of mortality in patients with PH as
compared with those without PH, after adjustment
for MR severity, clinical status, and LV systolic and
diastolic function. Nevertheless, management of
patients with secondary MR is still challenging in
case of severe asymptomatic MR.2,17
RESTING PULMONARY HYPERTENSION AND
MITRAL STENOSIS
The prevalence of PH in mitral stenosis (MS) is
related to MS severity and clinical status and
varies ranging from 14% to 33% for moderate
PH and 5% to 9.6% for severe PH.29,30 PH is
closely associated with heart failure symptoms
and recent studies confirmed the prognostic value
of PH in MS. 2,31 Yang and colleagues 32 suggested
that moderate and severe PH was associated with
adverse outcomes in MS after adjustment
of confounding factors. Similarly, Fawzy and
colleagues33 determined that severe PH
(sPAP >60 mm Hg) was associated with higher
risk of cardiovascular events at midterm
follow-up after percutaneous balloon. Patients
presenting with MS and moderate-severe PH
had a three-fold increased hazard ratio of death
at 10 years compared with patients with normal-
moderate PH (sPAP from 35 to 44 mm Hg). 34
Death resulted in most from congestive heart fail-
ure, acute pulmonary edema, and RV heart fail-
ure.2 PH is partially reversible after mitral valvular
replacement. Parvathy and colleagues35 explained
that not only did PH decrease after surgery but its
regression was in concert with improvement of RV
and LV remodeling (except LA enlargement) and
reduction of pulmonary vascular resistance. Path-
ologic changes might take longer to resolve and
differ in time and in degree from relative preopera-
tive PH.
There is no doubt that surgery or percutaneous
balloon is recommended for symptomatic signifi-
cant MS (valve area <1.5 cm2). 17 However, the
role of resting PH in management of mild or
asymptomatic MS differed according to European
and American guidelines. The American guidelines
propose to refer patients for surgery or percuta-
neous balloon before the progression of severe
PH, 36 whereas the European guidelines recom-
mend to warrant an annual follow-up for patients
presenting with symptomatic moderate MS (sur-
face area >1.5 cm 2 and mean transmitral gradient
<5 mm Hg) and to perform percutaneous balloon
in selective asymptomatic patients with high risk
of decompensation. 17
RESTING PULMONARY HYPERTENSION AND
AORTIC REGURGITATION
Aortic regurgitation (AR) is defined by a diastolic
reflux of blood from aorta to LV. PH appears at
advanced stage in natural history of AR, because
LV has the ability to adapt to pressure and volume
overload.37 With time, LV volume increases and LV
systolic function decreases with a decrease in LV
diastolic compliance and an increase in LV filling
pressure, which leads to increased sPAP.
The prevalence of PH in AR is, however, less
documented. Severe PH (sPAP >60 mm Hg) was
reported in 16% to 24% of patients with severe
chronic AR.38,39
The prognostic value of resting PH is not
completely elucidated. In a recent retrospective
study including 506 patients with severe AR,
Khandhar and colleagues38 showed that severe
PH was associated with LV dysfunction and func-
tional MR and returned to normal in most cases af-
ter surgery. AVR was an independent predictor of
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better survival at 5 years follow-up in patients
with both severe chronic AR and severe PH.
Consistently with previous data, Varadarajan and
colleagues40 described that 35% of patients with
severe AR had TR greater than 2. TR was related
to sPAP (PH was present in 25% of patients with
TR >2, whereas only 8% in patients with mild
TR). AVR in this subgroup was associated with a
better 5-year survival (78% vs 42%; <.001),P
despite higher PH.
However , PH pl ays a modest r ole in the curren t
managem ent of AR accordi ng to r ecomme nda-
tions. PH in AR sh ould be consi dered as a mar ker
of limited functiona l capaci ty, which mi ght
encour age clinician s to prop ose AVR.2
EXERCISE PULMONARY HYPERTENSION
AND VALVULAR HEART DISEASE
Resting PH is common in severe and symptom-
atic VHD and more rarely reported in asymptom-
atic patients ( and ).Figs. 2 3 19 Nevertheless,
patients can remain asymptomatic for a pro-
longed period of time at early stages of VHD
and develop either exercise-related symptoms,
such as dyspnea, before displaying heart failure.
Symptoms at exercise are related to increased
sPAP secondary to the increment of LV filling
pressure in relation to advanced grade of diastolic
dysfunction, severity of VHD, and RV function
adaptation capacity and pulmonary vascular
function. 2 Exercise echocardiography should
therefore contribute to unmask patients with hid-
den symptoms, revealing moderate or severe
VHD. It has been suggested that exercise echo-
cardiography was a useful tool to screen
exercise-induced PH (EIPH) and to identify pa-
tients with asymptomatic VHD at rest and higher
risk of further worsening.25 Previous study also
suggested that the kinetic of changes of exercise
PAP were a marker of adverse outcomes in VHD
rather than the level of exercise PAP.41
It was d emonstr ated that exercise echo cardi-
ography im prove d t he risk stra tific ation in asym p-
tomatic AS with preserve d LV fu nction. 42,43
Lancell otti and c olleag ues 43 found that EI PH
(sPAP >60 mm Hg) was pre sent in 55% of pa-
tients with sever e AS an d normal LVEF. After a
Fig. 2. Example of dynamic increase in systolic pulmonary arterial pressure during exercise in a patient with se-
vere aortic stenosis (peak aortic jet velocity >4 m/s). Ao Vel, aortic jet velocity; TTPG, transtricuspid pressure
gradient.
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mean follo w-up of 19 11 mont hs , EIPH was
indepe ndent ly associated with a two- fold in-
creas e risk of car diac even ts, even af ter adju st-
ment with de mograph ic d ata, r esting PH, an d
other exercise echocar dio graphi c parameters.
EIPH should he lp to individua lize a subgrou p of
high- ris k pa tient s with asymptom atic AS . Su rgery
might be rea sonable in cas e of in crea se g reater
than 20 mm Hg, whe reas a closer follow- up
should be warrant ed fo r patients withou t EI PH. 2
EIPH was more frequent in asymptomatic
patients with primary MR and preserved LV func-
tion and size, than resting PH. Magne and col-
leagues 44 described for the first time EIPH in 78
patients with moderate and severe primary MR.
Only 20% of patient with EIPH did not develop
symptoms after mean follow-up 19 months. A cut-
off value of 56 mm Hg for EIPH was the best pre-
dictor of symptoms. More recently, Kusunose and
colleagues 45 suggested that the combination of
EIPH (sPAP >54 mm Hg) and exercise-induced
RV dysfunction (tricuspid annular plane systolic
excursion (TAPSE) <19 mm) was a better predictor
of worst outcome that EIPH alone in patients with
asymptomatic degenerative MR. Exercise RV
dysfunction should be taken into account with
EIPH to predict outcomes in asymptomatic pa-
tients with primary MR. In addition, EIPH was a
predictive factor of cardiac events after MV repair.
To summarize, asymptomatic patients with pri-
mary moderate and severe MR and EIPH greater
than 60 mm Hg might be referred to surgery.
The prevalence of EIPH was estimated at 40% in
patients with secondary MR whatever LV func-
tion.46 Dynamic MR and subsequent dynamic PH
was a main predictive factor of worsening heart
failure and mortality in patients with chronic LV
dysfunction 47 and the established cutoff value for
the increase in sPAP is 21 mm Hg.48 Surgery might
be recommended in patients with EIPH, exercise-
induced MR, and planned coronary artery bypass.
In the absence of surgical decision, a closer
follow-up should be warranted.2
RIGHT VENTRICULAR FUNCTION AND
AORTIC STENOSIS
There are limited data regarding the prevalence
of RV dysfunction in AS. Galli and colleagues 49
found RV dysfunction (assessed by TAPSE
Fig. 3. Example of dynamic increase in systolic pulmonary arterial pressure and in mitral regurgitation severity
during exercise in a patient with secondary mitral regurgitation and left ventricular systolic dysfunction.
EROA, effective regurgitant orifice; TTPG, transtricuspid pressure gradient.
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<17 mm) in 48 of 200 patients (24%) presenting
with severe AS. Similarly, Koifman and col-
leagues50 reported 24% of RV dysfunction in a
larger study included 606 patients with severe
AS undergoing TAVR.
Sev era l m ec han ism s le ad ing to RV d ysf unc tio n
h a v e b e e n d e t e r m i n e d . A s c l a s s i c a l l y d e s c r i b e d
i n t h e V H D m o  d e l , L V r e m o d e l i n g c o n t r i b u t e d t o
t h e i n c r e a s e o f L V e n d - d i a s t o l i c p r e s s u r e a n d o f
P C W P a n d R V d y s f u n c t i o n r e s u l t e d d i r e c t l y f r o m
i n c r e a s e d s P A P a t f i n a l s t a g e s .5 1 I n d e e d , G a l l i
a n d c o l l e a g u e s 4 9 d e m o n s t r a t e d a m  a i n c o r r e l a -
t i o n b e t w e e n L V s y s t o l i c f u n c t i o n a n d R V p e r f o r -
m a n c e , r e l a t e d t o R V - L V i n t e  r d e p e n d e n c e ,
w h e r e a s s P A P w a s n o t a d e t e  r m i n a n t p r  e d i c t o r
o f R V f u n c t i o n . T h e y s u g g e s t e d t h a t t h e i n c r e a s e
o f s P A P n o t i c e d 1 y e a r a f t e r A V R o r T A V R m i g h t
be the c onse qu enc e of irr eve rsi ble st ruc tu ral
d a m a g e o f R V f u n c t i o n a n d m o r p h o l o g y , b e c a u s e
s i g n i f i c a n t l y R V d i l a t a t i o n a t a d v a n c e d R V f a i l u r e
e x c e e d e d a d a p t i v e s t a g e . B e f o r e i r r e v e r s i b l e
d a m a g e , R V f u n c t i o n a n d s i z e m a y i m p r o v e a f t e r
T A V R . 5 0
Data on the impact of RV function on outcomes
are limited. Galli and colleagues demonstrated
that a biventricular dysfunction (LVEF <50% and
TAPSE <17 mm) was a main predictor of mortality
in patients with severe AS independent of the
strategy of treatment chosen (hazard ratio, 4.08
[1.36–12.22]; .012), whereas RV dysfunctionP 5
alone was not a significant prognostic indicator.
In patients with AS referred to surgical AVR,
impaired RV function was a known adverse prog-
nostic factor, 8 whereas in patients with severe AS
undergoing TAVR, Koifman and colleagues50 did
not find a significant association between RV
dysfunction (assessed by TAPSE <17, s’
<9.5 cm/s, and fractional area change <0.35)
and mortality. In contrast, Testa and colleagues52
identified severe RV dilatation and dysfunction
(TAPSE <10 mm) as independent predictors of
1-year mortality in a larger study including pa-
tients with severe AS undergoing TAVR. Several
investigations emphasized the prognostic value
of RV dilatation in patients with severe AS under-
going TAVR.53,54 In addition, in patients with low
flow/low gradient AS, RV function has been
considered as marker of poor prognosis and
should be take into account in the decision-
making process.55
Nevertheless, whatever the method of assess-
ment of RV function (quantitative, semiquantita-
tive, or qualitative), RV dysfunction should be
considered as a marker of poor prognosis in
advanced VHD. The prognostic value and the
implication of RV in the strategy management
require further investigation.
RIGHT VENTRICULAR FUNCTION AND MITRAL
REGURGITATION
RV impairment has been commonly observed in
MR with or without LV dysfunction, in particular
in patients with large regurgitation.56 Le Tourneau
and colleagues 57 reported a prevalence of 30% of
RV dysfunction in patients with severe organic MR
referred to surgery. In a small study including 60
patients with high-risk functional MR undergoing
MitraClip, moderate and severe RV dysfunction
(TAPSE <16 mm and S’ <10 cm/s) was noticed in
37% of cases.58
RV dysfunction results from complex hemody-
namic and structural changes. Downstream,
chronic MR leads to LV volume overload with sub-
sequent LV enlargement and a decrease of inter-
ventricular septal function, and upstream, induces
an increase in LA pressure and with a subsequent
increase in sPAP and PCWP.5 It is speculated
that RV dysfunction may be the consequence of
RV pressure afterload. Nevertheless, several ob-
servations demonstrated that LV remodeling and
septal function were the main determinant of RV
function impairment, rather than PH.57
There are conflicting results regarding the prog-
nostic value of RV function in functional MR. Iso-
lated RV dysfunction has not been considered as
a predictive factor of early and long-term mortality
after surgery,59,60 whereas biventricular dysfunc-
tion (LVEF <60% and right ventricular ejection frac-
tion <35%) was associated with mid- and long-
term poor outcome in patients with severe organic
MR.57 In a recent study including 117 patients with
severe functional MR undergoing MitraClip,
Kaneko and colleagues 61 demonstrated that pre-
existing RV dysfunction (TAPSE <16 mm) was
significantly associated with all-cause mortality at
6 months follow-up despite a similar improvement
of MR regardless of RV function (hazard ratio,
1.975 [1.026–3.805]; .042). Conversely, GodinoP5
and colleagues58 reported that successful Mitra-
Clip procedure leads to a significant improvement
of RV function even in patients with baseline RV
dysfunction (TAPSE <16 mm and/or S’ <10 cm/s).
Reverse RV remodeling and reduced RV pressure
overload by regression of MR and sPAP might
explain its functional benefit. However, patients
with baseline RV dysfunction presented more
frequently with adverse events (stroke and heart
failure) as compared with patients without RV
dysfunction, as demonstrated by Neuss and col-
leagues.62 Moreover, data are lacking regarding
the prognostic value of RV dysfunction and long-
term effects of persistent MR after valvulopathy
correction on RV size and function.63 Previous
data showed that RV assessment should be useful
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to improve management process but further inves-
tigations are required.
RIGHT VENTRICULAR FUNCTION AND
MITRAL STENOSIS
RV function is frequently impaired in MS and re-
mains an essential step in the development of
clinical symptoms and in progression of the dis-
ease. 64,65 RV dysfunction may be attributed to
two different mechanisms. First, RV impairment
resulted from RV increased afterload and PH,
caused by increased LA pressure and chronic pul-
monary congestion. 7 Second, prior studies sug-
gested that RV dysfunction was related to
rheumatic involvement with subsequent myocyte
necrosis, replacement by fibrosis, and calcifica-
tion.66,67 Nevertheless, PH seemed to be a deter-
minant of RV impairment because changes in RV
function depended on the degree of PH. 68
Several studies demonstrated that RV function
improved in the early period and the improvement
seemed to continue at the late period after postop-
erative MS correction. Kumar and colleagues 69
analyzed RV strain and strain rate in 60 patients
with severe MS before and after valvulopathy
correction. They showed a significant increase in
peak systolic global and segmental RV strain at
basal, mid, and distal septum. There was no
change in strain rate, because strain rate did not
depend on load. They reported also a significant in-
crease of TAPSE and RV fractional area change,
whereas Tei index, s’, and Isolumic acceleration
were not affected by percutaneous valvuloplasty.
On the contrary, Drighil and colleagues 70 sug-
gested that Tei index and Fractional Area Change
(FAC) improved immediately after Percutaneous
balloon mitral valvuloplasty (PBMV) in 12 patients
presenting with MS. These discordant results
may be explained by the parameters used for RV
function evaluation, which depended or not on
load condition. 69 Nevertheless, it has been proved
that the release of mitral valve obstruction by
PBMV in patients in sinus rhythm led to decreased
LA volume, which contributed to reduce chronic
pulmonary congestion, PH, and RV afterload.71
Pre-existing RV dysfunction did not prevent clinical
improvement after PBMV.72 Further investigations
with larger populations are required to assess RV
remodeling and long-term outcomes of patients
with MS after percutaneous valvuloplasty.
RIGHT VENTRICULAR FUNCTION AND
AORTIC REGURGITATION
Data are limited concerning RV impairment in AR.
A study analyzed the consequences of LV volume
overload in 40 patients with severe AR on RV dia-
stolic function. Patients with elevated RV pressure
(>30 mm Hg) were excluded. RV diastolic function
was assessed by echocardiography, based on
Doppler-derived indexes and RV isovolumic relax-
ation time. Dourvas and colleagues 73 found
abnormal relaxation and RV filling along diastole
related in case of severe AR and suggested that
RV diastolic impairment was related to LV dilata-
tion and ventricular interdependence. To the best
our knowledge, the prognostic value of RV
dysfunction in severe AR has not yet been studied.
SUMMARY
VHD is the most frequent cause of PH. Regard-
less of VHD type, resting PH is closely linked
with clinical symptoms and poor prognosis.
Even though resting PH remains a classic indica-
tion of VHD correction, a more aggressive
approach might be proposed for selected pa-
tients with normal resting PAP but abnormal in-
crease during exercise. Finally, because the left
and right side of heart and lung vasculature
formed a global unit, PAP, LV, and RV function
are closely linked and should be considered and
evaluated as a whole unit.
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